Table 1.

Cell-free mRNA in DLBCL

References	Method	Sample	mRNA	Level	Result
Diagnosis
Garcia et al. [41]	RT-qPCR plasma	42 DLBCL 50 controls	CCND2, BCL2, MYC, LMO2 BCL6, FN1	Up NS	Higher level in DLBCL No difference
Zhao et al.[44]	RT-qPCR peripheral blood	63 DLBCL 32 controls	CREBBP	Up	Higher level in DLBCL
Response to therapy
Garcia et al. [41]	RT-qPCR plasma	42 DLBCL 50 controls	MYC CCND2, BCL2, LMO2, BCL6,FN1	Up NS	Higher level of MYC was associated with PR in patients with low-risk IPI No significant association with response to R-CHOP
Attia et al. [45]	RT-qPCR plasma	30 NHL (15 DLBCL) 20 controls	SOCS-3	Up	Higher level was associated with poor response to treatment (NR/PR versus CR) in NHL
Prognosis
Garcia et al. [41]	RT-qPCR plasma	42 DLBCL 50 controls	MYC, CCND2 CCND2, BCL2, MYC	Up Up	Higher level of MYC or CCND2 was associated with worse OS, with the latter only in low-risk IPI group Higher level of CCND2, BCL2 or MYC in patients with CR was associated with worse PFS
Ujj et al. [47]	RT-qPCR PAXgene blood RNA tube	25 DLBCL 35 controls	WT1	Up	Higher level in pre-, intra- or posttreatment samples was associated with worse DFS and OS

CR complete response, DFS disease-free survival, IPI international prognostic index, mRNA messenger RNA, NHL non-Hodgkin’s lymphoma, NR no response, NS not significant, OS overall survival, PFS progression-free survival, PR partial response, RT-qPCR reverse-transcription quantitative polymerase chain reaction